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Recombinant human interleukin 6 (IL-6) a lymphokine involved in the final differentiation of activated B-cells into anti- 
body-forming cells, greatly suppressed proliferation and induced differentiation of murine myeloid leukemia cells (Ml) 
into mature macrophage-like cells. When Ml cells were treated with IL-6, their growth was completely arrested as early 
as on day 2, and they were induced to differentiate morphologically into macrophage-like cells. Differentiation-associated 
properties such as phagocytic activity, adherence to the dish surface, Fc and C3 receptors, were also induced within 24 h 
by IL-6, and they reached their respective maximal levels on day 2 or 3. The potency of IL-6 in suppressing proliferation 
and inducing differentiation was much greater than that of la.25dihydroxyvitamin D, one of the most potent inducers 
of M 1 cells. The present report indicates that IL-6 is involved in the differentiation of not only B-cells but also myeloid 
leukemia cells. 
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1. INTRODUCTION 
The myeloid leukemia cell line (Ml), originally 
established by Ichikawa [l] from an SL mouse with 
myeloid leukemia, can be induced to differentiate 
into macrophages and granulocytes in vitro by 
several compounds such as protein inducers, 
bacterial lipopolysaccharides, polyribonucleotides, 
alkyl-lysophospholipids, glucocorticoids and 
la,25dihydroxyvitamin Ds [ lcu,25(OH)zD~]. Of 
these compounds, la,25(OH)~D3 is one of the 
most potent inducers of Ml cells in vitro [2]. Ad- 
ministration of lcu,25(OH)2D~ or its synthetic 
analogue, la-hydroxyvitamin D3, significantly 
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enhanced the survival time of mice inoculated with 
Ml cells in vivo [3]. 
Recently, much attention has been focused on 
the nature of the biological protein inducers called 
differentiation-inducing factors (DIFs). Various 
DIFs derived from conditioned media of tumor 
cells and mitogen-stimulated T-lymphocytes have 
been purified [4-61. Gearing et al. [7] reported the 
molecular cloning of the cDNA of a murine DIF. 
The amino acid sequence of the DIF was different 
from any other hematopoietic cytokines identified 
to date. In addition, Tomida et al. [8] have shown 
that recombinant human granulocyte colony- 
stimulating factor (G-CSF) induces the macro- 
phage differentiation of Ml cells. The relationship 
of these protein factors is a matter of debate. 
B-cell stimulatory factor 2 (BSF-2) was original- 
ly found in the supernatants of mitogen- or 
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antigen-stimulated mononuclear cell cultures 
[9,10], and it subsequently was identified as a T- 
cell derived lymphokine involved in the final dif- 
ferentiation of activated B-cells into antibody- 
forming cells [l 11. Recently, the cDNA for BSF-2 
was cloned [12] and the mutual identity of the 
amino acid sequence in BSF-2 and other cytokines 
such as 25 kDa-protein, interferon ,& and plasma- 
cytoma growth factor was established [ 13-151. 
Moreover, it has been demonstrated that BSF-2 
acts on T-cells [16-181, hepatocytes [19,20] and 
hematopoietic stem cells [21]. These results in- 
dicate that BSF-2 has an important role not only in 
the immunoglobulin production of B-cells but also 
in the regulation of growth and differentiation of 
various other cells. It is now proposed that BSF-2 
be called interleukin 6 (IL-6). 
We report here that recombinant human IL-6 is 
a potent inducer of differentiation of Ml cells into 
mature macrophages. IL-6 was much more potent 
than la,25(OH)~Ds in suppressing growth and in- 
ducing differentiation of Ml cells. 
2. MATERIALS AND METHODS 
2.1. Drugs 
Recombinant human IL-6 (rlL-6) was prepared by expressing 
a cDNA for BSF-2 [12] in E. cob, followed by further purifica- 
tion. The specific activity was determined as 5.2 x lo9 U/g by 
using the IL-6 responsive human B lymphoblastoid cell line, 
SKW6CL4 [ll]. la,25(OH)rDx was the generous gift of Dr 1. 
Matsunaga, Chugai Pharmaceutical Co., Tokyo. 
2.2. Cells and cell culture 
Ml cells, clone T22, were kindly donated by Dr M. Hozumi 
(Saitama Cancer Center Research Institute, Saitama, Japan). 
They were cultured at 37°C under 5% CO2/95% air in Eagle’s 
minimal essential medium supplemented with twice the normal 
concentrations of amino acids and vitamins and 10% heat- 
inactivated calf serum (Chiba Serum Institute, Chiba, Japan). 
They were transferred every 2-3 days. 
2.3. Measurement of phagocytic activity 
After Ml cells were washed with serum-free medium, they 
were incubated for 4 h with polystyrene latex particles (2 &ml, 
average diameter 0.81 pm; Difco) at 37°C under 5% COZ in air. 
After incubation, the cells were washed three times with Cal+- 
and Mg*‘-free phosphate-buffered saline [PBS( -)I, and the 
number of phagocytic cells among at least 200 cells was counted 
with a hemocytometer. 
2.4. Detection of Fc and C3 receptors 
Cells with Fc or C3 receptors were determined by the method 
of Lotem and Sachs [22]. Ml cells (5 x 10’) were mixed with 
2.5 x 10’ rabbit anti-sheep erythrocyte antibody-coated 
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erythrocytes or antibody and mouse complement-coated 
erythrocytes in 0.5 ml of serum-free medium. After incubation 
for 30 min at 37”C, the percentage of rosette-forming cells with 
4 or more erythrocytes per cell was counted with a hemocyto- 
meter. At least 200 cells were counted. 
2.5. Determination of adherent cells 
After culture for the indicated time, non-adherent cells were 
collected. The cell-layer was gently rinsed with pre-warmed 
serum-free medium and the recovered cells were combined with 
the non-adherent cells. Adherent cells were collected by pipet- 
ting with ice-cold PBS( -). Adherent cells were expressed as the 
percentages of total cells by counting cell numbers of both 
adherent and non-adherent cells. 
2.6. Determination of growth of non-adherent MI cells pre- 
treated with either rIL-6 or Ic~,25(0H)~D~ 
Cells were seeded at 1 x 10S/ml and incubated for 3 days with 
100 U/ml of rIL-6 or 12 nM la,25(OH)zDj. On day 3, the 
respective non-adherent cells were collected as described above 
(2.5), washed 3 times with serum-free medium, and reseeded at 
1 X lO’/ml in the control medium without either inducer. The 
number of viable cells was determined on each day by counting 
the cells which were not stained with trypan blue. 
3. RESULTS 
When Ml cells were cultured for 3 days with 
l-100 U/ml of rIL-6, cell growth was strikingly in- 
hibited in time- and dose-dependent manners. The 
remaining cells were attached to the dish surface. 
Most of the untreated control cells were myelo- 
blastic with a large round nucleus (fig.lA). With 
the treatment with rIL-6 for 3 days, the cells 
changed their morphology into macrophage-like 
cells with abundant cytoplasm (fig.lB). Fig.2 
shows time courses of change in the expression of 
typical markers for macrophage differentiation by 
rIL-6. Treatment with 100 U/ml of rIL-6 greatly 
induced phagocytic activity within 24 h, and 90% 
of the cells exhibited the activity on day 2. Forma- 
tion of Fc and C3 receptors was also increased by 
rIL-6 in a time-dependent manner. The percentage 
of adherent cells in the culture treated with 
100 U/ml of rIL-6 attained a plateau of 70% on 
day 2. Addition of polymyxin B did not affect the 
induction of differentiation by rIL-6, indicating 
that the influence of endotoxin that might have 
been contaminated in this culture system can be ex- 
cluded (not shown). 
We have reported that 0.12-120 nM lcu, 
25(0H)~Dx markedly suppresses growth and in- 
duces differentiation of Ml cells dose-dependently 
[2]. la,25(OH)zDj is one of the most potent 
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Fig. 1. Morphology of Ml cells incubated for 3 days without (A) or with (B) 100 U/ml of rlL-6. Stained with May-Griinwald-Giemsa; 
x 600. 
known inducers of Ml cells [2]. Therefore, we 
compared the effects of rIL-6 and 1&,25(OH)zD3 
on growth and differentiation of Ml cells (table 1). 
rIL-6 at l-100 U/ml inhibited growth of Ml cells 
dose-dependently. Phagocytic activity was 
significantly increased by the treatment with as lit- 
tle as 1 U/ml of rIL-6, and it attained a maximal 
level of 90% at 100 U/ml. Significant increases in 
Fc and C3 receptors were induced by 33 U/ml of 
Culture (days) 
Fig.2. Time course of change in the differentiation-associated 
properties of Ml cells incubated with 100 U/ml of rlL-6. On 
the indicated culture days, percentages of the cells expressing 
phagocytic activity (0). Fc receptor (A), C3 receptor (T) and 
adherence to the dish surface (m) were determined as described 
in section 2. Data are the means f SE of three independent ex- 
periments. 
rIL-6, and more than half of the cells exhibited the 
respective receptors at 100 U/ml. l~u,25(OH)zD~ at 
1.2-120 nM also suppressed cell growth and in- 
duced differentiation in a dose-dependent manner 
(table 1). The maximal inhibition of cell growth 
and stimulation of differentiation by rIL-6 were 
always much greater than those induced by 
lcu,25(OH)~D3 (table 1). 
Finally, we examined whether non-adherent Ml 
cells after pretreatment with rIL-6 or 
1~,25(OH)zD3 can proliferate in the control 
medium without either inducer. Non-adherent cells 
collected from the culture medium and also by 
washing adherent cell layers after preculture with 
12 nM 1~,25(0H)~Dj proliferated again, whereas 
those after preculture with 100 U/ml of rIL-6 did 
not grow at all (fig.3). This indicates that rIL-6 af- 
fected both adherent and non-adherent cells. 
4. DISCUSSION 
The present study clearly demonstrates that IL-6 
is involved not only in the final differentiation of 
activated B-cells into antibody-secreting cells, but 
also in the growth and differentiation of myeloid 
leukemia cells. It is likely that IL-6 inhibits growth 
and induces differentiation of Ml cells by a 
receptor-mediated mechanism. Taga et al. [23] 
have reported that IL-6 receptors are present not 
only in the activated B-cells but also in some 
established cell lines including human promyelo- 
19 
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Table 1 
Dose-response effects of rIL-6 and lru,25(OH)zDj on the growth and differentiation of Ml cells 
Compounds added Concentration Cell 
number 
Ethanol (control) 
rIL-6 
0.1% 
1 U/ml 
10 U/ml 
33 U/ml 
100 U/ml 
100 
81.4 + 0.5* 
50.0 f 5.3* 
31.4 f 3.3* 
21.7 f 1.3* 
la,25(OH)zD3 1.2 nM 64.1 + 2.6* 
12 nM 52.7 + 2.0* 
120 nM 50.4 + 2.1: 
Phagocytic 
activity (070) 
1.4 k 0.4 
8.4 + 0.4* 
16.8 + 1.6* 
50.8 f 2.4* 
90.8 + 1.7* 
19.6 k 4.2** 
53.4 k 5.1* 
52.5 + 3.6* 
Fc receptor 
(%) 
C3 receptor 
(70) 
0.3 c 0.2 
0.3 * 0.2 
1.3 + 0.5 
20.3 f 3.8* 
52.5 * 2.1* 
1.8 k 0.6 
19.2 k 2.8* 
20.4 z+ 3.6* 
0.6 + 0.3 
0.7 + 0.5 
1.9 + 0.3** 
30.5 + 4.0* 
53.6 + 6.4* 
2.9 + 1.3 
20.6 k 0.9* 
22.1* 1.5* 
Values are expressed as the means I SE of 3-6 experiments. After culture for 3 days, the cell number and the percentages of phagocytic 
activity and the cells with Fc or C3 receptors were determined as described in section 2. The cell number was expressed as percentages 
of the control culture. The statistical significance of the difference from the control was analysed by Student’s t-test. * p<O.OOS; 
** p<o.o5 
cytic leukemia cells (HL-60). Although the exact 
mechanism of the IL-6 action in the myeloid 
leukemia cell differentiation has to be elucidated in 
the future, the marked in vitro effects of IL-6 on 
the growth and differentiation of Ml cells suggest 
the possibility that this cytokine will be useful for 
the treatment of leukemic animals and humans. 
It has been reported that there are some 
similarities in the amino acid sequence between 
IL-6 and G-CSF [12]. Like IL-6, G-CSF has been 
found to induce differentiation of Ml cells [8]. 
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Ikebuchi et al. [21] also reported that IL-6 controls 
proliferation of multipotent hematopoietic pro- 
genitors. These results further support the hypo- 
thesis that IL-6 is involved in the regulation of 
growth and differentiation of hematopoietic cells. 
Recently, several protein factors that induce dif- 
ferentiation of Ml cells (DIFs) have been purified 
from conditioned media of tumor and normal 
cells. We reported that one of the DIFs purified 
from conditioned media of mouse spleen cell 
cultures treated with concanavalin-A exhibited po- 
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Fig.3. Comparison of the growth activity of non-adherent Ml cells after pretreatment with either rIL-6 or la,25(OH)zD3. [A] Ml cells 
were incubated for 3 days with vehicle (o), 100 U/ml of rlL-6 (0) or 12 nM lcu,25(OH)zD, (A). On the days indicated, viable cells 
were counted with a hemocytometer. [B] On day 3 of the culture in [A], non-adherent cells were collected from the cultures treated 
with rIL-6 (0) or lcu,25(OH)2D3 (A), washed thoroughly, and subcultured for 4 days in the control medium without either inducer. 
Data are the means of three wells. Each SE was smaller than the size of the symbol. 
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tent bone-resorbing activity [6]. Thus, IL-6 may 
have an important role in the differentiation of 
osteoclast progenitors into multinucleated 
osteoclasts. This possibility is currently under in- 
vestigation in our laboratories. 
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